The Commercial Impact of REMS Relief: Nplate/Promacta Sales Spike After Risk Management Changes
This article was originally published in RPM Report
Executive Summary
Nplate and Promacta aren’t the most important products sold by Amgen and GSK. But they are among the fastest growing in 2012—thanks to a decision by FDA to relax post-market controls at the end of 2011. The change underscores the case for a different approach to REMS in oncology, and may point the way forward for broader use of the new tools in a less intrusive way.
You may also be interested in...
FDAAA Impact Analysis (Year 4): The REMS Retreat Continues - For Now
As the fifth year of the REMS era begins, FDA is imposing mandatory programs less frequently than it did even in the first year after the law creating formal risk management plans took effect. But there are some new trends to watch, including the evolution of REMS classes and the emergence of products with REMS-in-waiting.
REMS 2.0: FDA Refining New Drug Safety Tools
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.
Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop
FDA and the oncology community will continue discussions about the role of REMS in cancer care. The agency is clearly taking pushback from providers seriously.